Literature DB >> 14718324

Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.

Abhay F Srinivasan1, Lawrence Rice, John R Bartholomew, Chandhiran Rangaswamy, Lucy La Perna, James E Thompson, Scott Murphy, Kelty R Baker.   

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a common, often catastrophic, syndrome that produces the most hypercoagulable of states. Emerging therapeutic strategies use alternative anticoagulants; warfarin's place is being reexamined. Early in the course of warfarin therapy, there may be net procoagulant effects because of the inhibition of protein C. With HIT, it has been suggested that unopposed warfarin can precipitate venous limb gangrene. There are also reports of warfarin-induced skin necrosis. We seek to confirm and increase awareness of the risks of warfarin with HIT.
METHODS: We describe 6 patients with HIT seen at 3 medical centers in whom frank or impending venous limb gangrene, central skin necrosis, or both were temporally related to warfarin initiation.
RESULTS: At warfarin initiation, 5 patients had recognized HIT and 1 had it recognized later. Complications emerged after 2 to 7 days, and consisted of warfarin-induced skin necrosis (n = 5) and venous limb gangrene (n = 2); 1 patient had both. This emerged with unopposed warfarin in 4 patients and as a direct thrombin inhibitor was being withdrawn in 2. All had supratherapeutic international normalized ratios. One patient required leg and breast amputations, and another one died.
CONCLUSIONS: Because of the early effects on protein C, warfarin can precipitate venous limb gangrene and/or skin necrosis in the extreme hypercoagulable milieu of HIT. With HIT, unopposed warfarin should be avoided and caution is needed during transition from a direct thrombin inhibitor. Warfarin should be initiated at modest doses in patients with HIT after platelet recovery. Implications extend to warfarin initiation with other thrombotic diatheses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718324     DOI: 10.1001/archinte.164.1.66

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  29 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Heparin-induced thrombocytopenia: overview and treatment.

Authors:  Daniel A Zinkovsky; Marilena S Antonopoulos
Journal:  P T       Date:  2008-11

4.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

5.  Hats Off to HIT: A Case Report.

Authors:  Akhwand Shakeel Ahmad; Dhia Jaber Al-Layla; Manjula Dhinakar
Journal:  Oman Med J       Date:  2012-05

6.  Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).

Authors:  John R Bartholomew; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

7.  Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.

Authors:  John R Bartholomew; Carolynn E Pietrangeli; Marcie J Hursting
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

9.  A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Authors:  Karen M Curzio; A Cheng-Lai; V Kheyfets; M Sinnet; H H Billett
Journal:  J Thromb Thrombolysis       Date:  2008-09-25       Impact factor: 2.300

10.  Warfarin-induced penile necrosis in a patient with heparin-induced thrombocytopenia.

Authors:  In Ho Chang; Moon Soo Ha; Byung Hoon Chi; Yong Wook Kown; Sang-Jae Lee
Journal:  J Korean Med Sci       Date:  2010-08-16       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.